This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Haydon, R. C. Articles by He, T.-C. Search for Related Content PubMed PubMed Citation Articles by Haydon, R. C. Articles by He, T.-C.

Nuclear Receptor Agonists As Potential Differentiation Therapy Agents for Human Osteosarcoma¹

Molecular Oncology Laboratory, Department of Surgery, The University of Chicago Medical Center, Chicago, Illinois 60637

Purpose: This study was designed to investigate whethernuclear receptor agonists can be used as potential differentiationtherapy agents for human osteosarcoma.

Experimental Design: Four osteosarcoma cell lines (143B, MNNG/HOS, MG-63, and TE-85) were treated with proliferator-activated receptor (PPAR) agonists, troglitazone and ciglitazone, and a retinoid X receptor (RXR) ligand, 9-cis retinoic acid. The proliferation and induction of apoptosis in the treated cells were assessed, as was the induction of alkaline phosphatase, a differentiation marker of osteoblasts.

Results: The expression of PPAR was readily detected in all tested osteosarcoma lines. On treatment with the PPAR and RXR ligands, all four osteosarcoma lines exhibited a significantly reduced proliferation rate and cell viability. Among the four lines, 143B and MNNG/HOS were shown to be more sensitive to ligand-induced apoptosis, as demonstrated by the Crystal Violet and Hoechst staining assays. Of the three tested ligands, troglitazone was shown to be the most effective in inducing cell death, followed by 9-cis retinoic acid. Moreover, a strong synergistic effect on the induction of cell death was observed when both troglitazone and 9-cis retinoic acid or ciglitazone and 9-cis retinoic acid were administered to osteosarcoma cells. Troglitazone was shown to effectively induce alkaline phosphatase activity, a well-characterized hallmark for osteoblastic differentiation.

Conclusions: Our findings suggest that PPAR and/or RXR ligands may be used as efficacious adjuvant therapeutic agents for primary osteosarcoma, as well as potential chemopreventive agents for preventing the recurrence and metastasis of osteosarcoma after the surgical removal of the primary tumors.

This article has been cited by other articles:

				G. Kristiansen, J. Jacob, A.-C. Buckendahl, R. Grutzmann, I. Alldinger, B. Sipos, G. Kloppel, M. Bahra, J. M. Langrehr, P. Neuhaus, et al. Peroxisome Proliferator-Activated Receptor {gamma} Is Highly Expressed in Pancreatic Cancer and Is Associated With Shorter Overall Survival Times. Clin. Cancer Res., November 1, 2006; 12(21): 6444 - 6451. [Abstract] [Full Text] [PDF]

				M. A. Peraza, A. D. Burdick, H. E. Marin, F. J. Gonzalez, and J. M. Peters The Toxicology of Ligands for Peroxisome Proliferator-Activated Receptors (PPAR) Toxicol. Sci., April 1, 2006; 90(2): 269 - 295. [Abstract] [Full Text] [PDF]

				M. Platica, E. Ivan, J. F. Holland, A. Ionescu, S. Chen, J. Mandeli, P. D. Unger, and O. Platica A pituitary gene encodes a protein that produces differentiation of breast and prostate cancer cells PNAS, February 10, 2004; 101(6): 1560 - 1565. [Abstract] [Full Text] [PDF]

				R. Gorlick, P. Anderson, I. Andrulis, C. Arndt, G. P. Beardsley, M. Bernstein, J. Bridge, N.-K. Cheung, J. S. Dome, D. Ebb, et al. Biology of Childhood Osteogenic Sarcoma and Potential Targets for Therapeutic Development: Meeting Summary Clin. Cancer Res., November 15, 2003; 9(15): 5442 - 5453. [Abstract] [Full Text] [PDF]

				E. J. Kim, K. S. Park, S. Y. Chung, Y. Y. Sheen, D. C. Moon, Y. S. Song, K. S. Kim, S. Song, Y. P. Yun, M. K. Lee, et al. Peroxisome Proliferator-Activated Receptor-{gamma} Activator 15-Deoxy-{Delta}12,14-Prostaglandin J2 Inhibits Neuroblastoma Cell Growth through Induction of Apoptosis: Association with Extracellular Signal-Regulated Kinase Signal Pathway J. Pharmacol. Exp. Ther., November 1, 2003; 307(2): 505 - 517. [Abstract] [Full Text] [PDF]